Batteries capable of quick charging as fast as fossil fuel vehicles are becoming a vital issue in the electric vehicle market. However, conversion-type materials promising as a next-generation anode have many problems to satisfy fast charging and long-term cycles due to their low conductivity and large irreversibility despite a high theoretical capacity. Here, we report effective strategies for a SnO-based anode to enable rapid-charging, long-cycle, and high reversible capacity. The quantum size of SnO nanoparticles uniformly embedded within a 3D conductive carbon matrix as a prerequisite for high reversible capacity increases the interdiffusion layer and facilitates a highly reversible conversion reaction between LiO/Sn and SnO. In particular, the Sn-C chemical bond achieves ion-site control and direct electron transfer, enabling boost charging. Further, the robust and porous structure of the binder-free three-dimensional electrode buffers the massive volume expansion during Li insertion/desertion and allows for multidimensional rapid-ion diffusion. As a result, our quantum SnO anode delivers a high reversible capacity of about 753 mAh g with a 468% capacity increase after 4000 cycles at 10 C. It also presents a gradually increasing capacity up to 548 mAh g even at 20 C and superior cyclability over 20 000 cycles in capacity stabilization. This study will contribute to designing aerofilm-based conversion-type electrodes for fast charging devices.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsnano.1c08011DOI Listing

Publication Analysis

Top Keywords

high reversible
12
reversible capacity
12
fast charging
8
capacity
7
charging
5
unlocking rapid
4
rapid charging
4
charging extended
4
extended lifetimes
4
lifetimes li-ion
4

Similar Publications

Background: Diabetic conditions are associated with alterations in brain functions like memory deficits through processes like synaptic dysfunction in the hippocampus. Administering a combination of silver nanonaringenin and vitamin E appears promising since they are known to prevent diabetes and memory deficits in previous studies, and nanoformulation of naringenin may be one way to improve delivery and bioavailability of naringenin in the brain. This study investigated the effects of co-administering silver nanonaringenin and vitamin E against memory deficits and synaptic dysfunction in the hippocampus of a mice model of high-fat diet and streptozotocin (HS).

View Article and Find Full Text PDF

Background: A pathological hallmark of Alzheimer's disease (AD) is the accumulation of amyloid-beta peptide (Aß). Potential treatments targeting Aß production such as γ-secretase inhibitors have had limited success. A promising alternative approach involves addressing early synaptic dysfunction by modulating molecules like striatal-enriched protein tyrosine phosphatase (STEP), whose levels and activity are upregulated by Aß.

View Article and Find Full Text PDF

Background: Neurological disorders are at epidemic levels in the world today. Various proteins are being targeted for the development of novel molecular therapeutics; however, no small-molecule inhibitors have been discovered. Recent studies suggest that there are few molecules in clinical trials for various secretase (α, β, and γ), caspase, and calpain inhibitors.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

UCSD, San Diego, CA, USA.

Cerebral beta-amyloid accumulation is the key initiator of Alzheimer's disease (AD) pathology. Most familial early-onset AD mutations in the APP, PSEN1/2 genes increase the ratio of Abeta42:Abeta40, which drives beta-amyloid accumulation in the brain. In 2001, the late Steve Wagner, Maria Kounnas, and I directed an agnostic high-throughput screen for compounds that would reverse the Abeta42:Abeta40, ratio, and discovered the first non-NSAID (second generation) gamma secretase modulators (GSM) at TorreyPines Therapeutics.

View Article and Find Full Text PDF

Background: Almost all primary care providers (PCPs) believe screening for mild cognitive impairment (MCI) and dementia in older patients is important. However, there are significant barriers in primary care, including low provider confidence in their assessment skills, time constraints, competing priorities, and poor financial incentives. Consequently, PCPs report conducting cognitive assessments for less than half of patients over 60 years of age.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!